CBG vs CBD

Nobody has run a head-to-head human trial, so there is no evidence that either one is stronger or better. What the science can say is that CBD has far more research behind it and one FDA-approved medical use, while CBG has a single small trial in our registry. "Better" needs an outcome the science has not established for either. For a buyer, a well-made product, a current COA and a clinician's view say more than any boast on the box. (not medical advice) Catalogue in progress

CBG and CBD are different molecules with different laboratory targets, and CBD's research record runs far deeper; what they share is that neither is intoxicating. They also sit on different branches of the plant's chemistry. CBG is the neutral form of CBGA, the plant's "mother" precursor, while CBD comes off a separate branch. The sharpest contrast turns up at the 5-HT1A serotonin receptor, where lab work shows CBG acting as a blocker (Cascio 2010), commonly described as the opposite of what CBD is reported to do there. Established

No; in lab studies they act on different receptors. In vitro, CBG activates the α2-adrenoceptor and blocks both 5-HT1A and CB1 (Cascio 2010), and it modulates TRP channels (De Petrocellis 2011). CBD is reported to reach a wider and different set of targets. The α2 result comes with a practical warning: because CBG affects α2-adrenoceptors, mind blood pressure on cardiovascular medication. Demonstrated · in vitro

The evidence has not established either one for anxiety or for inflammation. On anxiety, our registry holds one small human trial of CBG, and CBD is marketed hard for it, yet both remain unestablished for these OTC uses and no study has tested the two against each other. Inflammation is earlier ground still. The data for both stop at preclinical signals, which for CBG means a mouse colitis model (Borrelli 2013). A label promising either outcome has run ahead of its evidence. (not medical advice) Catalogue in progress

Standard drug tests look for THC and its metabolite, and CBG and CBD fall outside the panel. The risk comes from trace THC, up to 0.3%, in full-spectrum products of either type, which may build up and trigger a positive result. Broad-spectrum and isolate products lower that risk, and the certificate of analysis (COA) shows the THC content of the batch you are actually buying. Low

In the US, hemp-derived CBG and CBD (≤0.3% delta-9 THC) are generally federally legal as of 2026 under the 2018 Farm Bill. The states are another matter: their laws vary and keep changing. One prescription CBD medicine is FDA-approved, while the status of OTC foods and supplements depends on the cannabinoid and the jurisdiction. Informational, not legal advice; check the rules where you sell or buy. Established

Informational only — not our claims, and not advice. The statements on this page about potential effects, benefits, or uses reflect claims made by third parties (manufacturers, media, traditional use, or preliminary research) and are presented for educational and informational purposes only. CBG Atlas does not make, adopt, endorse, or affirm these claims, and does not represent them as fact. These statements have not been evaluated by the Food and Drug Administration (or any regulator) and are not intended to diagnose, treat, cure, or prevent any disease. Nothing here is medical, legal, or professional advice; cannabinoid effects, safety, and legal status vary by person, product, and jurisdiction and can change over time. Consult a qualified professional before making any health or purchasing decision. Where we can, we show how strong the evidence is and cite the source; where evidence is thin or absent, we say so. Peregrine Biopharma funds the platform and holds no editorial authority.

Report a safety event: if you experienced a possible adverse effect from a cannabinoid product, please report it via the platform's "Report a safety event" path.

Verified anchors: Cascio 2010 (PMID 20002104) · De Petrocellis 2011 (PMID 21175579) · Borrelli 2013 (PMID 23415610) · Appendino 2008.